Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
Animals
Autoradiography
Binding, Competitive
Cerebral Cortex
/ diagnostic imaging
Fluorine Radioisotopes
/ chemistry
Humans
Ligands
Mammals
/ metabolism
Membrane Glycoproteins
/ metabolism
Nerve Tissue Proteins
/ metabolism
Positron-Emission Tomography
Radiopharmaceuticals
/ chemistry
Rats, Sprague-Dawley
Staining and Labeling
Synapses
/ metabolism
Time Factors
Tissue Distribution
Micro-PET imaging
PET radioligand
Preclinical characterization
Radioligand binding
SV2A
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
16
11
2019
medline:
8
7
2021
entrez:
16
11
2019
Statut:
ppublish
Résumé
Current synaptic vesicle 2A (SV2A) positron emission tomography (PET) imaging agents include the nanomolar affinity probes [ Radioligand binding methods were employed in mammalian brain homogenates to determine the SV2A affinity (K [ Taken together, these data suggest [
Identifiants
pubmed: 31728839
doi: 10.1007/s11307-019-01428-0
pii: 10.1007/s11307-019-01428-0
doi:
Substances chimiques
Fluorine Radioisotopes
0
Ligands
0
Membrane Glycoproteins
0
Nerve Tissue Proteins
0
Radiopharmaceuticals
0
Sv2a protein, rat
0
Fluorine-18
GZ5I74KB8G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
832-841Références
Bajjalieh SM, Frantz GD, Weimann JM, McConnell S, Scheller RH (1994) Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci 14:5223–5235
doi: 10.1523/JNEUROSCI.14-09-05223.1994
Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM (1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci 96:15268–15273
doi: 10.1073/pnas.96.26.15268
Jahn R, Fasshauer D (2012) Molecular machines governing exocytosis of synaptic vesicles. Nature 490:201–207
doi: 10.1038/nature11320
Mendoza-Torreblanca JG, Vanoye-Carlo A, Phillips-Farfán BV et al (2013) Synaptic vesicle protein 2A: basic facts and role in synaptic function. Eur J Neurosci 38:3529–3539
doi: 10.1111/ejn.12360
Vogl C, Tanifuji S, Danis B, Daniels V, Foerch P, Wolff C, Whalley BJ, Mochida S, Stephens GJ (2015) Synaptic vesicle glycoprotein 2A modulates vesicular release and calcium channel function at peripheral sympathetic synapses. Eur J Neurosci 41:398–409
doi: 10.1111/ejn.12799
Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101:9861–9866
doi: 10.1073/pnas.0308208101
Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, Frycia AM, Moureau FG, Klitgaard HV, Gillard MR, Fuks B, Michel P (2004) Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 47:530–549
doi: 10.1021/jm030913e
von Rosenstiel P (2007) Brivaracetam (UCB 34714). Neurotherapeutics 4(1):84–87
Ohno Y, Tokudome K (2017) Therapeutic role of synaptic vesicle glycoprotein 2A (SV2A) in modulating epileptogenisis. CNS Neurol Disord Drug Targets 16:463–471
pubmed: 28393712
Löscher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H (2016) Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs 30:1055–1077
doi: 10.1007/s40263-016-0384-x
Lever SZ, Fan KH, Lever JR (2017) Tactics for preclinical validation of receptor-binding radiotracers. Nucl Med Biol 44:4–30
doi: 10.1016/j.nucmedbio.2016.08.015
Hargreaves RJ, Hoppin J, Sevigny J, Patel S, Chiao P, Klimas M, Verma A (2015) Optimizing central nervous system drug development using molecular imaging. Clin Pharmacol Ther 98:47–60
doi: 10.1002/cpt.132
Patel S, Hamill TG, Connolly B, Jagoda E, Li W, Gibson RE (2007) Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [
doi: 10.1016/j.nucmedbio.2007.07.009
Patel S, Ndubizu O, Hamill T, Chaudhary A, Burns HD, Hargreaves R, Gibson RE (2005) Screening cascade and development of potential positron emission tomography radiotracers for mGluR5: in vitro and in vivo characterization. Mol Imaging Biol 7:314–323
doi: 10.1007/s11307-005-0005-4
Patel S, Hammil T, Hostetler E et al (2003) An invitro assay for predicting successful imaging radiotracers. Mol Imaging Biol 5:65–71
doi: 10.1016/S1536-1632(03)00041-6
Patel S, Gibson R (2008) In vivo site-directed radiotracers: a mini-review. Nucl Med Biol 35:805–815
doi: 10.1016/j.nucmedbio.2008.10.002
Gillard M, Fuks B, Leclercq K, Matagne A (2011) Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol 664:36–44
doi: 10.1016/j.ejphar.2011.04.064
Warnier C, Lemaire C, Becker G, Zaragoza G, Giacomelli F, Aerts J, Otabashi M, Bahri MA, Mercier J, Plenevaux A, Luxen A (2016) Enabling efficient positron emission tomography (PET) imaging of synaptic vesicle glycoprotein 2A (SV2A) with a robust and one-step adiosynthesis of a highly potent 18F-labeled ligand ([
doi: 10.1021/acs.jmedchem.6b00905
Nabulsi NB, Mercier J, Holden D, Carre S, Najafzadeh S, Vandergeten MC, Lin SF, Deo A, Price N, Wood M, Lara-Jaime T, Montel F, Laruelle M, Carson RE, Hannestad J, Huang Y (2016) Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain. J Nucl Med 57:777–784
doi: 10.2967/jnumed.115.168179
Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, Dhaher R, Matuskey D, Baum E, Holden D, Spencer DD, Mercier J, Hannestad J, Huang Y, Carson RE (2016) Imaging synaptic density in the living human brain. Sci Transl Med 8:348ra96
doi: 10.1126/scitranslmed.aaf6667
Finnema SJ, Nabulsi NB, Mercier J, Lin SF, Chen MK, Matuskey D, Gallezot JD, Henry S, Hannestad J, Huang Y, Carson RE (2018) Kinetic evaluation and test-retest reproducibility of [
doi: 10.1177/0271678X17724947
Li S, Cai Z, Wu X, Holden D, Pracitto R, Kapinos M, Gao H, Labaree D, Nabulsi N, Carson RE, Huang Y (2019) Synthesis and in vivo evaluation of a novel PET radiotracer for imaging of synaptic vesicle glycoprotein 2A (SV2A) in nonhuman primates. ACS Chem Neurosci 10:1544–1554
doi: 10.1021/acschemneuro.8b00526
Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K
doi: 10.1016/0006-2952(73)90196-2
Patel S, Hamill T, Hostetler E et al (2003) An in-vitro assay for predicting successful imaging radiotracers. Mol Imaging Biol 5:65–71
doi: 10.1016/S1536-1632(03)00041-6
Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A, Mathy FX, Mercier J, Stockis A, Carson RE, Klitgaard H (2016) Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 57:201–209
doi: 10.1111/epi.13267
Eckelman WC, Gibson RE (1993) The design of site-directed radiopharmaceuticals for use in drug discovery. In: Burns HD, Gibson RE, Dannals R, Siegl P (eds) Nuclear imaging and drug discovery, development and approval. Birkhauser, Boston, pp 114–134
Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH (2018) Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol 75:1215–1224
doi: 10.1001/jamaneurol.2018.1836
Dawson TM, Golde TE, Lagier-Tourenne C (2018) Animal models of neurodegenerative diseases. Nat Neurosci 21:1370–1379
doi: 10.1038/s41593-018-0236-8
Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, de Strooper B, Hardy J, Vassar R, Winblad B, Saido TC (2017) APP mouse models for Alzheimer’s disease preclinical studies. EMBO J 36:2473–2487
doi: 10.15252/embj.201797397
Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, Alagille D, Sandiego CM, Papin C, Marek K, Seibyl JP, Tamagnan GD, Barret O (2019) Development and in vivo preclinical imaging of fluorine-18-labeled synaptic vesicle protein 2A (SV2A) PET tracers. Mol Imaging Biol 21:509–518
doi: 10.1007/s11307-018-1260-5